Sign In
Buy LLY
$1,116.11
-5.06 (-0.451%)
At Close: Aug 04, 2026
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions
05:00am, Tuesday, 09'th Jun 2026
Convatec (LSE: CTEC), a leading medical products and technologies company focused on solutions for the management of chronic conditions; The Eli Lilly and Compa
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions
04:00am, Tuesday, 09'th Jun 2026
LONDON & BOSTON--(BUSINESS WIRE)--Convatec (LSE:CTEC), a leading medical products and technologies company focused on solutions for the management of chronic conditions; The Eli Lilly and Company Foun
Why Eli Lilly Stock Climbed to a New All-Time High Today
09:13pm, Monday, 08'th Jun 2026
Investors are excited about retatrutide's potential. Rival drugmakers are finding it difficult to keep pace with the healthcare leader.
Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway
06:15pm, Monday, 08'th Jun 2026
The S&P 500 has climbed in the double digits since President Donald Trump's inauguration. But certain elements point toward a potential slowdown ahead.
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?
05:23pm, Monday, 08'th Jun 2026
Prevention could become Eli Lilly's next multibillion-dollar growth driver. Antibiotic resistance is increasing demand for preventive vaccine solutions.
In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg In ACHIEVE-2 and ACHIEVE-5, Foundayo deliver
Eli Lilly stock rises as Retatrutide data boosts obesity drug lead
01:50pm, Monday, 08'th Jun 2026
Shares of Eli Lilly LLY climbed about 4% on Monday after the drugmaker unveiled encouraging new clinical data for its next-generation obesity treatment, retatrutide. This has reinforced investor confi
Why Eli Lilly, In A Buy Zone, Is Still The 'Clear Winner' Of The 'Weight Loss Olympics'
01:28pm, Monday, 08'th Jun 2026
Eli Lilly emerged as the "clear winner" from the ADA meeting last weekend in New Orleans, an analyst said following the event.
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
12:14pm, Monday, 08'th Jun 2026
Zealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients. That's good news for Eli Lilly and Novo Nordisk, which curren
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
10:01am, Monday, 08'th Jun 2026
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Lilly shares jump as analysts see retatrutide data extending obesity market edge
07:06am, Monday, 08'th Jun 2026
Eli Lilly shares jumped 4% premarket on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting it to extend the drugmaker's l
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug
06:16am, Monday, 08'th Jun 2026
Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.
Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.
05:44am, Monday, 08'th Jun 2026
The weight-loss rivals provided positive updates on their obesity treatments but to differing reactions among investors.
Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success
05:35am, Monday, 08'th Jun 2026
A late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.
Top 50 High-Quality Dividend Growth Stocks For June 2026
04:51am, Monday, 08'th Jun 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD,
